A Phase 1, Open Label, 3-treatment Period, 1-sequence, Cross-over Study to Evaluate Pharmacokinetics, Safety, and Tolerability After Single Ascending Oral Doses of SAR441566 in Healthy Adult Japanese Male Participants.
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Balinatunfib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Sanofi
- 18 Aug 2023 Status changed from recruiting to completed.
- 26 May 2023 Status changed from not yet recruiting to recruiting.
- 17 May 2023 New trial record